CRITICAL THERAPEUTICS, INC. PLACEMENT AGENT AGREEMENTSubscription Agreement • October 27th, 2006 • Critical Therapeutics Inc • Pharmaceutical preparations • New York
Contract Type FiledOctober 27th, 2006 Company Industry Jurisdiction
CONSULTING AGREEMENTConsulting Agreement • October 27th, 2006 • Critical Therapeutics Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 27th, 2006 Company Industry JurisdictionTHIS CONSULTING AGREEMENT (the “Agreement”), dated as of October 25, 2006 (the “Effective Date”) is entered into by Critical Therapeutics, Inc., a Delaware corporation with offices at 60 Westview Street, Lexington, MA 02421 (the “Company”), and M. Cory Zwerling, an individual residing at 21 Hutchins Road, Carlisle, MA 01741 (the “Consultant”).
October 25, 2006Confidential Separation Letter Agreement • October 27th, 2006 • Critical Therapeutics Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 27th, 2006 Company Industry JurisdictionThis Confidential Separation Letter Agreement and General Release (the “Agreement”) sets forth and confirms the terms of the separation package that Critical Therapeutics, Inc. (the “Company”) is willing to offer you (“you” or the “Employee”) as a result of your voluntary resignation to establish an amicable arrangement for ending your employment relationship, to release the Company from any claims, and to permit you to receive severance pay and related benefits. Please read this Agreement carefully. If you are willing to agree to its terms, please sign and date in the space provided on the signature page and return it to Scott Townsend, the Company’s Vice President of Legal Affairs and General Counsel, so that your separation benefits can begin.
FORM OF WARRANT AGREEMENTForm of Warrant Agreement • October 27th, 2006 • Critical Therapeutics Inc • Pharmaceutical preparations • New York
Contract Type FiledOctober 27th, 2006 Company Industry JurisdictionTHIS WARRANT AGREEMENT (the “Agreement”) is dated as of October ___, 2006 between Critical Therapeutics, Inc., a Delaware corporation (the “Company”), and Mellon Investor Services LLC, a New Jersey limited liability company (the “Warrant Agent”).